<DOC>
	<DOC>NCT00637715</DOC>
	<brief_summary>Collection of the data on the safety and efficacy of the once daily administration of the alfuzosin preparation /Alfetim UnoÂ® l0 mg/ at patients with lower urinary tract symptoms/complaints rendering possible the presence of benign prostatic hyperplasia, in the course of everyday practice</brief_summary>
	<brief_title>Once Daily Given Alfuzosin in the Treatment of BPH</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Sexually active male patient with lower urinary tract symptoms indicative of severe BPH, at whom disturbances of urinary retention and urination are present Necessity of surgical intervention immediately or within 12 months because of BPH The patient has earlier /within 6 months/ obtained treatment because of BPH The patient did not improve on earlier alpha1 blocker treatment Known hypersensitivity to alfuzosin Orthostatic hypotension in the history Concomitant application with another alpha1 blocker Hepatic insufficiency /AST, ALT 3 fold of the upper limit of the normal value/ Severe renal insufficiency /se creatinine greater than or equal to 150 umol/l/ Intestinal obstruction /because of the castor oil content of the drug/ Tumorous disease Severe, life threatening state The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>